Evidence map›Paper›PMID 29084142›Full record

ReviewNutrients2017

Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs.

Narcis Tribulova, Barbara Szeiffova Bacova, Tamara Egan Benova, Vladimir Knezl, Miroslav Barancik, Jan Slezak

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Fish oil supplementation modifies the genetic potential for blood lipids.medRxiv : the preprint server for health sciences · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Narcis TribulovaInstitute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, P.O. Box 104, 84005 Bratislava, Slovakia. narcisa.tribulova@savba.sk.
Barbara Szeiffova BacovaInstitute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, P.O. Box 104, 84005 Bratislava, Slovakia. barbara.bacova@savba.sk.
Tamara Egan BenovaInstitute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, P.O. Box 104, 84005 Bratislava, Slovakia. tamara.benova@savba.sk.
Vladimir KnezlInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 84104 Bratislava, Slovakia. vladimir.knezl@savba.sk.
Miroslav BarancikInstitute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, P.O. Box 104, 84005 Bratislava, Slovakia. miroslav.barancik@savba.sk.
Jan SlezakInstitute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, P.O. Box 104, 84005 Bratislava, Slovakia. jan.slezak@savba.sk.
Slovak Academy of Sciences · SKInstitute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omega-3 polyunsaturated fatty acids (PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are permanent subjects of interest in relation to the protection of cardiovascular health and the prevention of the incidence of both ventricular and atrial arrhythmias. The purpose of this updated review is to focus on the novel cellular and molecular effects of omega-3 PUFAs, in the context of the mechanisms and factors involved in the development of cardiac arrhythmias; to provide results of the most recent studies on the omega-3 PUFA anti-arrhythmic efficacy and to discuss the lack of the benefit in relation to omega-3 PUFA status. The evidence is in the favor of omega-3 PUFA acute and long-term treatment, perhaps with mitochondria-targeted antioxidants. However, for a more objective evaluation of the anti-arrhythmic potential of omega-3 PUFAs in clinical trials, it is necessary to monitor the basal pre-interventional omega-3 status of individuals, i.e., red blood cell content, omega-3 index and free plasma levels. In the view of evidence-based medicine, it seems to be crucial to aim to establish new approaches in the prevention of cardiac arrhythmias and associated morbidity and mortality that comes with these conditions.

Indexed as

AnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacDisease Models, AnimalDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3HumansMeta-Analysis as TopicRandomized Controlled Trials as TopicAnti-Arrhythmia AgentsDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3atrial fibrillationconnexin-43omega-3 indexomega-3 PUFAsventricular fibrillation

Identifiers

PMID29084142
PMCPMC5707663
OpenAlexW2765414781

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.